Tiantan Bio (600161.SS)

Executive Summary

Tiantan Biological Products Co., Ltd. (600161.SS) is a leading Chinese biopharmaceutical company with a strong commercial footprint in blood products (e.g., albumin, immunoglobulin, coagulation factors) and vaccines (e.g., influenza). The company generated substantial revenue from these segments and has a market capitalization of ~$29.4B. In addition to its marketed portfolio, Tiantan Bio is advancing a pipeline of three drug candidates. The most notable is a Phase 1 clinical trial (NCT07080775) evaluating an allogeneic iPSC-derived dopaminergic neural progenitor cell injection for Parkinson's disease, which is currently recruiting. Other pipeline assets include Endostatin (Phase 2 completed in 2016) and CN-105 (Phase 2, status unknown). The company's established manufacturing and plasma collection infrastructure provides a solid foundation for growth, while its early-stage cell therapy program represents a potential long-term value driver. Tiantan Bio's ability to navigate regulatory environments in China and expand its product offerings will be key to sustaining its market position.

Upcoming Catalysts (preview)

• Q4 2026Interim safety/efficacy data from Phase 1 iPSC-derived cell therapy for Parkinson's disease30% success
• TBDPublication of Phase 2 results for CN-105 in intracerebral hemorrhage (final analysis)50% success